Mylan N.V. (MYL) reported its financial results for the quarter ended March 31, 2020, on Monday before the market opens. The company reaffirmed its financial guidance for the full-year 2020. The results were driven by overall volume growth, which was favorably impacted by increased customer buying patterns and patient prescription trends resulting from the COVID-19 pandemic, primarily in its Europe segment. Looking ahead, Mylan remains on track to close the pending combination with Pfizer’s Upjohn Business in the second half of the year. Take a look at the company's earnings in graphical format here
